Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2014
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome
Murielle Roussel, Valérie Lauwers-Cances, Nelly Robillard, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 12, 2026
Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma
Benjamin Hebraud, Charis Charalampous, Ricardo Parrondo, et al.
Journal of Cancer
|
March 26, 2014
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
Guillemette Fouquet, Benjamin Hebraud, Sylvain Garciaz, et al.
Immunotherapy
|
November 24, 2020
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison
Philippe Moreau, Benjamin Hebraud, Thierry Facon, et al.
Blood
|
February 1, 2015
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience
Benjamin Hebraud, Florence Magrangeas, Alice Cleynen, et al.
Leukemia
|
January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon, Gordon Cook, Saad Z Usmani, et al.
Leukemia & Lymphoma
|
July 13, 2017
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria
Guillemette Fouquet, Kym Ie Snell, Stéphanie Guidez, et al.
Haematologica
|
April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients
Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.
Blood
|
March 24, 2025
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results
Jill Corre, Laure Vincent, Philippe Moreau, et al.
Blood
|
October 31, 2015
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Marie-Lorraine Chretien, Jill Corre, Valerie Lauwers-Cances, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2014
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome
Murielle Roussel, Valérie Lauwers-Cances, Nelly Robillard, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 12, 2026
Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma
Benjamin Hebraud, Charis Charalampous, Ricardo Parrondo, et al.
Journal of Cancer
|
March 26, 2014
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
Guillemette Fouquet, Benjamin Hebraud, Sylvain Garciaz, et al.
Immunotherapy
|
November 24, 2020
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison
Philippe Moreau, Benjamin Hebraud, Thierry Facon, et al.
Blood
|
February 1, 2015
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience
Benjamin Hebraud, Florence Magrangeas, Alice Cleynen, et al.
Leukemia
|
January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon, Gordon Cook, Saad Z Usmani, et al.
Leukemia & Lymphoma
|
July 13, 2017
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria
Guillemette Fouquet, Kym Ie Snell, Stéphanie Guidez, et al.
Haematologica
|
April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients
Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.
Blood
|
March 24, 2025
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results
Jill Corre, Laure Vincent, Philippe Moreau, et al.
Blood
|
October 31, 2015
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Marie-Lorraine Chretien, Jill Corre, Valerie Lauwers-Cances, et al.
Page
of 3